BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Week in Review: Hisun to Invest $163 Million into JV With Pfizer Inc. (PFE)


5/29/2012 9:21:01 AM

by Richard Daverman, PhD

May 26, 2012 -- Zhejiang Hisun Pharma will invest $163 million for a 51% stake in its JV with Pfizer, implying a value of $319 million for the venture; Yantai Dongcheng Biochemicals completed a $110 million IPO on Shenzhen’s Small and Medium-Sized Enterprises Board; ASLAN Pharma of Singapore in-licensed global rights to a potential rheumatoid arthritis treatment from the Spanish pharma Almirall; Guangzhou Xiangxue Pharma gained China rights to a potential oncology drug developed by Kinex Pharma of the US; ChinaBio® and EBD Group, co-producers of the ChinaBio® Partnering Forum, held May 22-24 in Suzhou, announced that the fourth edition of the event attracted 719 attendees from 432 companies and 23 countries who engaged in more than 1100 one-to-one meetings; a team of China researchers has developed a new DNA vaccine that simultaneously protected against tuberculosis and HIV in animal tests; the stock price of Shanghai Pharma suffered large losses after media reports alleged the company has committed accounting fraud; Sanofi will begin a Phase I clinical trial in China next year of a novel drug that targets liver cancer that it in-licensed from SIBS for a reported $60 million upfront payment; and China now has more drug representatives than the US. More details….

Stock Symbols: (SHA: 600267) (NYSE: PFE) (SHE: 002675) (SHE: 300147) (SHA: 601607; HK: 2607) (NYSE: SNY)



Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES